1.40
-0.01 (-0.71%)
| Previous Close | 1.41 |
| Open | 1.41 |
| Volume | 2,051,166 |
| Avg. Volume (3M) | 3,147,770 |
| Market Cap | 375,030,912 |
| Price / Earnings (Forward) | 28.74 |
| Price / Sales | 1.18 |
| Price / Book | 10.14 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -24.51% |
| Operating Margin (TTM) | 23.85% |
| Diluted EPS (TTM) | -0.210 |
| Quarterly Revenue Growth (YOY) | 75.80% |
| Total Debt/Equity (MRQ) | 795.72% |
| Current Ratio (MRQ) | 2.23 |
| Operating Cash Flow (TTM) | -34.81 M |
| Levered Free Cash Flow (TTM) | 12.96 M |
| Return on Assets (TTM) | -4.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Akebia Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.10 |
|
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 3.59% |
| % Held by Institutions | 38.96% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ADAMS ADRIAN | 1.02 | - | 35,700 | 36,414 |
| FRIESON RON | 1.02 | - | 35,700 | 36,414 |
| ROGERS MICHAEL W | 1.02 | - | 35,700 | 36,414 |
| SMITH CYNTHIA | 1.02 | - | 35,700 | 36,414 |
| WOLF MYLES | 1.02 | - | 35,700 | 36,414 |
| ZUMWALT LEANNE M | 1.02 | - | 35,700 | 36,414 |
| Aggregate Net Quantity | 214,200 | |||
| Aggregate Net Value ($) | 218,484 | |||
| Aggregate Avg. Buy ($) | 1.02 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ADAMS ADRIAN | Director | 17 Jun 2026 | Acquired (+) | 35,700 | 1.02 | 36,414 |
| ZUMWALT LEANNE M | Director | 17 Jun 2026 | Acquired (+) | 35,700 | 1.02 | 36,414 |
| FRIESON RON | Director | 17 Jun 2026 | Acquired (+) | 35,700 | 1.02 | 36,414 |
| ROGERS MICHAEL W | Director | 17 Jun 2026 | Acquired (+) | 35,700 | 1.02 | 36,414 |
| SMITH CYNTHIA | Director | 17 Jun 2026 | Acquired (+) | 35,700 | 1.02 | 36,414 |
| WOLF MYLES | Director | 17 Jun 2026 | Acquired (+) | 35,700 | 1.02 | 36,414 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |